HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Epigenome editing could one day silence PCSK9 and treat other diseases

Gokhan Can · Jun 28, 2026 · ♥ 3 reactions · 0 comments · original Facebook post
PCSK9, ezetimibe & newer drugs
AI summary & key facts

Shares a Nature news feature on start-ups developing epigenome-editing therapies, noting PCSK9 silencing as a possible cholesterol application. No trial data in the post.

Epigenome editing one day might silence pcsk9 completely, but it has even bigger potential in numerous other conditions.

Paper · Nature · 2026CRISPR’s next act: the companies editing the epigenome to treat diseaseA handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder.nature.com
#pcsk9
← newer: LDL-C is cumulative exposure: lowering it earlier and longerolder: Mergen and Hasselbalch review heart drugs, supplements and l →